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Abstract
This study was conducted to examine the frequency, phenotype,
and functional profile of T lymphocytes that proliferate in
response to type I collagen (CI) in patients with scleroderma
(SSc). Peripheral blood mononuclear cells (PBMCs) from SSc
patients, healthy controls, and rheumatoid arthritis disease
controls were labeled with carboxy-fluorescein diacetate,
succinimidyl ester (CFSE), cultured with or without antigen
(bovine CI) for 14 days, and analysed by flow cytometry. Surface
markers of proliferating cells were identified by multi-color flow
cytometry. T-cell lines were derived after sorting for proliferating
T cells (CFSElow). Cytokine expression in CI-responsive T cells
was detected by intracellular staining/flow cytometry and by
multiplex cytokine bead assay (Bio-Plex). A T-cell proliferative
response to CI was detected in 8 of 25 (32%) SSc patients, but
was infrequent in healthy or disease controls (3.6%; p = 0.009).
The proliferating T cells expressed a CD4+, activated (CD25+),
memory (CD45RO+) phenotype. Proliferation to CI did not
correlate with disease duration or extent of skin involvement. T-
cell lines were generated using in vitro CI stimulation to study
the functional profile of these cells. Following activation of CI-
reactive T cells, we detected intracellular interferon (IFN)-γ but
not interleukin (IL)-4 by flow cytometry. Supernatants from the T-
cell lines generated in vitro contained IL-2, IFN-γ, GM-CSF
(granulocyte macrophage-colony-stimulating factor), and
tumour necrosis factor-α, but little or no IL-4 and IL-10,
suggesting that CI-responsive T cells express a predominantly
Th1 cytokine pattern. In conclusion, circulating memory CD4 T
cells that proliferate to CI are present in a subset of patients with
SSc, but are infrequent in healthy or disease controls.
Introduction
Systemic sclerosis (scleroderma) (SSc) is characterised by
immune activation, microvascular dysfunction, and progres-
sive fibrosis. Increased deposition of type I collagen (CI) is evi-
dent in the skin and involved internal organs of patients with
SSc [1].
Cellular components and soluble mediators of the adaptive
immune system play a central role in disease pathogenesis [2].
Activated T cells and levels of soluble interleukin (IL)-2 recep-
tor are increased in the peripheral blood of patients with SSc
[3-5]. In the skin, cellular infiltration precedes dermal fibrosis
and consists of activated T lymphocytes, plasma cells, and
macrophages [6,7]. Helper (CD4) T cells predominate, and
the degree of cellular infiltration correlates with both the
degree and progression of skin thickening [8]. Memory T cells
are also present in the inflammatory infiltrate of affected inter-
nal organs, such as the lungs [9].
There is evidence to suggest that the activation of T cells in
SSc is antigen-driven [10]. Analysis of the T-cell receptor rep-
ertoire in skin biopsies of patients with SSc revealed that T
cells have undergone clonal expansion. Indeed, the presence
of a dominant T-cell clone in skin biopsies obtained from a
patient at different time points and from different skin regions
ACR = American College of Rheumatology; APC = antigen-presenting cell; BSA = bovine serum albumin; CFSE = carboxy-fluorescein diacetate, 
succinimidyl ester; CI = type I collagen; IFN-γ = interferon-γ ; IL = interleukin; PBMC = peripheral blood mononuclear cell; PBS = phosphate-buffered 
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implies that the putative driving antigen is persistently present
and widely distributed [11].
Putative antigens in SSc include DNA topoisomerase I, RNA
polymerases, and microbial products. CI has also been impli-
cated as an autoantigen in SSc, and several reports suggest
that patients with SSc exhibit cellular immunity to CI [12-14].
Peripheral blood mononuclear cells (PBMCs) from the major-
ity of patients produce chemotactic cytokines when cultured
with CI [12]. CI-stimulated PBMCs from patients with SSc
produce IL-6 [13] and IL-2; the latter is predominantly derived
from CD4+, but not CD8+, T cells [14]. McKown et al. reported
that PBMCs from most patients with SSc produce IFN-γ, IL-
10, or both when cultured with the α chains of CI [15]. Lym-
phocyte proliferation to CI, measured by tritiated thymidine
incorporation, has been reported to occur in a subset (25%)
of patients with SSc [12], although this was not confirmed by
other investigators [16].
The study of antigen-specific lymphocytes is challenging
because these cells are rare in the peripheral blood. Recently,
a flow cytometric method that allows the concurrent analysis
of the phenotype and proliferative response of antigen-specific
T cells was used to study the immune response to a specific
antigen [17]. We employed a similar method to demonstrate
that, in a subset of patients with SSc but rarely in normal or dis-
ease controls, circulating CI-responsive CD4 T cells are
present. T cells proliferating in the presence of CI express an
activated, memory phenotype and secrete Th1 cytokines.
Materials and methods
Research subjects
Patients with a diagnosis of limited or diffuse SSc according
to the criteria of the American College of Rheumatology (ACR)
(1980) [18] were recruited from the Rheumatology Clinics of
the University of Tennessee Health Science Center (Memphis,
TN, USA). Patients with SSc-like illness related to environmen-
tal, ingested, or injected agents, localised scleroderma, or
eosinophilic fasciitis were excluded from the study. Healthy
controls were recruited from among staff and allied health
workers at the University of Tennessee. Disease controls, all
carrying a diagnosis of rheumatoid arthritis according to ACR
criteria [19], were recruited from our Rheumatology Clinics. All
subjects gave written consent, and the research protocol was
approved by the Institutional Review Board.
Reagents
Bovine CI and β1,2 chain (dimers formed by the component α-
1 and α-2 chains) were provided by the Collagen Core facility
of the Rheumatic Disease Research Core at the University of
Tennessee Health Science Center. Bovine CI was prepared
as previously reported [15,20]. The homogeneity of CI was
confirmed by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis and by cyanogen bromide peptide mapping. Fluor-
ochrome-labeled antibodies specific for human lymphocyte
surface markers (CD3, CD4, CD8, CD28, CD45RO, CD25,
CD212/IL-12R β2, and CD49a) and human cytokines (IFN-γ
and IL-4) were obtained from BD Biosciences (San Jose, CA,
USA). Human rIL-2 was obtained from Sigma-Aldrich (St.
Louis, MO, USA). Cell culture medium ('complete medium')
consisted of RPMI-1640, 2 mM l-Glutamine, 1% non-essential
amino acids, 1% sodium pyruvate, 100 U/ml penicillin, 100
µg/ml streptomycin, 25 mM HEPES Buffer, and 55 µM 2-mer-
captoethanol (all from Invitrogen, Carlsbad, CA, USA) and 9%
fetal calf serum (Sigma-Aldrich).
PBMC isolation, CFSE labeling, and cell culture
PBMCs were isolated from venous blood by density-gradient
centrifugation using Ficoll-Paque (GE Healthcare, Little Chal-
font, Buckinghamshire, UK). Cells were immediately labeled
with carboxy-fluorescein diacetate, succinimidyl ester (CFSE)
(Sigma-Aldrich), using a modification of the method described
by Turcanu et al. [17]. Briefly, PBMCs were resuspended at 1
× 107 cells per ml in phosphate-buffered saline (PBS) contain-
ing 0.1% bovine serum albumin (BSA) (Sigma-Aldrich). Prior
to staining, an aliquot of CFSE (5 mM in dimethyl sulfoxide)
was thawed, diluted 1:10 with 1 M HEPES buffer (Invitrogen),
and added to the cell suspension (labeling concentration was
5 µM). PBMCs were vortexed and incubated with CFSE for 10
minutes in a 37°C water bath, and the dye excess was washed
once with 0.1% BSA/PBS followed by a wash with complete
medium. PBMCs were cultured in complete medium in 24-well
plates at a concentration of 3 × 106/2 ml medium per well in a
37°C, 5% CO2 incubator. CI was added to the cell culture at
a final concentration of 10 µg/ml, and β1,2 chain was added
in a separate well (final concentration of 2.5 µg/ml). Control
wells received only PBS. At day 7, half the medium from all
wells was replaced with fresh medium supplemented with IL-
2 (20 U/ml). PBMCs were cultured for a total of 12 to 14 days
and were then harvested, washed, and analysed by flow
cytometry. In the first 13 patients with SSc studied, PBMCs
were cultured with CI or PBS control. In the next 12 patients
who were enrolled, PBMCs were cultured with CI, purified
β1,2 chain, or PBS control. We included β1,2 chain in these
subsequent experiments to demonstrate that T-cell prolifera-
tion was not due to a collagen contaminant. For all the RA and
normal subjects, PBMCs were cultured with CI, purified β1,2
chain, or PBS control. Correlation between the results
obtained with CI and β1,2 chain was excellent. (Individual sub-
ject PBMCs responded either to both collagen preparations or
to neither preparation.)
A positive proliferative response to CI was defined as a
greater-than-twofold increase in proliferating T cells (CFSElow)
in response to antigen.
Flow cytometry
Surface markers of proliferating cells were identified by multi-
color flow cytometry with fluorochrome-labeled antibodies to
CD3, CD4, CD8, CD28, CD45RO, CD25, CD212 (IL-12RAvailable online http://arthritis-research.com/content/8/4/R136
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β2), and CD49a. Briefly, lymphocytes were stained for 30 min-
utes at 4°C with PerCP- (peridinin-chlorophyll-protein) or PE-
(phycoerythrin) conjugated antibodies. Appropriate isotype
controls were used to determine background staining. After
washing of unbound antibody, samples were analysed on a
FACScan flow cytometer (Becton, Dickinson and Company,
Franklin Lakes, NJ, USA), and the frequencies of cell subsets
were calculated using WinMDI software (Joseph Trotter; The
Scripps Research Institute, La Jolla, CA, USA).
Generation of T-cell lines
CI-responsive T-cell lines were generated from the PBMCs of
three patients which demonstrated a positive in vitro prolifera-
tive response to CI (as defined above). After 14 days of culture
with antigen, cells were collected and stained with anti-CD4
PE. CFSElowCD4+ cells or CFSEhighCD4+ cells were then
sorted using a FACSCalibur (BD Biosciences) CFSElowCD4+
cells were further expanded by two to three rounds (every 10
days) of in vitro activation with irradiated (4,000 rad) autolo-
gous PBMCs (106/well), antigen (CI or β1,2 chain), and IL-2
(20 U/ml). After the last round of activation, cells were rested
for 10 days prior to additional experiments.
Intracellular cytokine detection by flow cytometry
Resting T-cell lines (106/ml in 48-well plates) were restimu-
lated with PMA (phorbol 12-myristate 13-acetate) (50 ng/ml)
and ionomycin (500 ng/ml) in the presence of brefeldin A (10
µg/ml; GolgiPlug; BD Biosciences) for 5 hours. The cells were
then harvested, stained with antibodies to surface markers
(CD4) for 30 minutes, fixed (20 minutes, 4% paraformalde-
hyde/PBS), and stored at 4°C overnight. Next, the cells were
permeabilised (BD Perm/Wash; BD Biosciences) and then
stained with cytokine-specific antibodies at 4°C for 30 min-
utes. Parallel samples were incubated with appropriate intrac-
ellular isotype controls. Samples were run on a flow cytometer,
and at least 30,000 events were collected. Data were ana-
lysed using the WinMDI 2.8 software (The Scripps Research
Institute).
Cytokine array
In separate experiments, resting CI-specific T-cell lines were
activated in vitro for 72 hours with plate-bound anti-CD3 (10
µg/ml) and anti-CD28 (1 µg/ml). Cells were incubated at a
concentration of 2 × 106 cells per ml in a 48-well plate, and
supernatants were harvested after 48 hours of culture. T-cell
line supernatants were then assayed for cytokines using a mul-
tiplex cytokine bead array system (cat. no. 171-A11050 Bio-
Plex; Bio-Rad, Hercules, CA, USA) according to the manufac-
turer's instructions. The reaction mixture was read using the
Bio-Plex protein array reader, and data were analysed with the
Bio-Plex Manager software program in the Rheumatic Disease
Research Core Center, Veterans Affairs Medical Center
(Memphis, TN, USA).
Statistical analysis
Descriptive statistics were generated using SigmaStat soft-
ware (version 2.03; SPSS Inc., Chicago, IL, USA). The propor-
tion of patients and controls demonstrating reactivity to CI was
compared using the Fisher exact test (SigmaStat software).
Results
Patient demographics
We enrolled 25 patients with SSc for this study. The mean age
was 55.4 (± 10.9) years, and 72% of the subjects were
female. Most patients had limited cutaneous disease, and
eight (32%) had diffuse disease. The average SSc disease
duration was 10.29 (± 9.8) years (Table 1).
CI stimulation results in the expansion of CFSElowCD4+ T 
lymphocytes
PBMCs from SSc donors were labeled with CFSE and then
cultured with and without CI. To further expand the CI-specific
population, IL-2 was added at day 7 and the cells were har-
vested at day 14. In the CI-treated cultures, we observed the
expansion of a CFSElowCD4+ T lymphocyte population. A
much smaller population of CFSElowCD4+ T lymphocytes was
present in the PBMCs cultured without antigen, suggesting
that the CFSElowpopulation emerges due to antigen-induced
Table 1
Patient demographics
Characteristic n (%)
Mean age (years) 55.4 ± 10.9
Gender
Male 7 (28%)
Female 18 (72%)
Race
Caucasian 19 (76%)
African American 6 (24%)
Disease duration (years) 10.29 ± 9.8
Skin involvement
Diffuse disease 8 (32%)
Mean skin score (MRSS) 24.5 ± 8.2
Limited disease 17 (68%)
Mean skin score (MRSS) 13 ± 5.9
Raynaud's 24 (96%)
Arthralgias 23 (88%)
Internal organ involvement
Gastrointestinal 24 (96%)
Pulmonary 15 (60%)
Renal 2 (8%)
Cardiac 2 (8%)
MRSS, modified Rodnan skin score.Arthritis Research & Therapy    Vol 8 No 4    Warrington et al.
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proliferation. Other studies have shown that this method cor-
relates very well with cell proliferation measured by [3H]-thymi-
dine incorporation [17]. A distinct advantage of this method is
that proliferating cells are viable and can be used for additional
experiments such as immunophenotyping and functional anal-
yses. To confirm our findings, concurrent experiments were
conducted in select patients, using highly purified β1,2 chain
(heterodimers of α-1 and α-2 chains) of CI as antigen, and
similar results were obtained (Figure 1a). A positive prolifera-
tive response to CI was defined as a greater-than-twofold
increase in proliferating cells (CFSElow) in the presence of CI.
Approximately one third of the patients with SSc demon-
strated reactivity to CI, whereas CI reactivity was rare in con-
trol cohorts (p = 0.009). Only one of 19 healthy individuals
demonstrated significant T-cell proliferation to CI, and none of
the patients with rheumatoid arthritis reacted to CI in vitro
Figure 1
T-Cell Proliferation to C1 T-Cell Proliferation to C1. (a) Peripheral blood mononuclear cell proliferation monitored using carboxy-fluorescein diacetate, succinimidyl ester 
(CFSE) labeling. Representative dot plot of CFSE/CD4 double-labeling demonstrates increased T-cell proliferation (CFSElow) in response to (in vitro 
culture with) type I collagen (CI) or β1,2 chain. (b) CI-reactive lymphocytes express an activated, memory phenotype. Representative histogram dem-
onstrates that the majority of CFSElow (that is, antigen-specific proliferating T cells) express CD45RO and CD25 (right panels) compared with the 
CFSEhigh (non-responsive to antigen) T cells (left panels). Grey shaded areas represent staining with the appropriate isotype control. PBS, phos-
phate-buffered saline.Available online http://arthritis-research.com/content/8/4/R136
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(Table 2). Among those patients exhibiting a proliferative
response to CI, the mean percentage of proliferating CD4 T
cells increased from 11% (± 9.97) in control wells to 28.7%
(± 19.4) in the CI-stimulated wells (p = 0.04).
In the patients with SSc, there was no significant difference in
disease duration between the CI responder group (median
disease duration 10 years) and the CI non-responders
(median disease duration 6 years; p = 0.561). There was no
correlation between CI responsiveness and pattern of skin
involvement (limited versus diffuse; p = 0.359). None of the
SSc-related disease manifestations was predictive of an
immune response to CI in vitro, except for a trend toward more
l u n g  f i b r o s i s  i n  t h e  C I  r e s p o n d e r s .  O f  t h e  C I  r e s p o n d e r s ,
87.5% had pulmonary involvement, whereas only 47% of the
non-responders had this complication (p = 0.09). It is possible
that in a study with a larger sample size a significant difference
would be observed.
Furthermore, we used three-color (CFSE, PE, and PercP) flow
cytometry to compare the cell surface characteristics of CI-
responsive T cells (CFSElow) with the non-proliferating cells
(CFSEhigh). In patients who exhibited a significant proliferative
response to CI, PBMCs (at day 14 of culture with CI) were
stained with fluorochrome-conjugated antibodies to CD3,
CD4, CD25, CD45RO, and CD212 (IL-12 receptor β2).
Using flow cytometry and by electronically gating on the
CFSElow population, we determined that CFSElow cells were
CD3+CD4+ T cells that preferentially expressed the activation
marker CD25 (IL-2 receptor α) and the memory T-cell marker
CD45RO. As expected, the CFSEhigh, non-proliferating popu-
lation included both naïve and memory T cells that were not
activated and did not express the IL-2R (Figure 1b). Although
CD212 has been implicated as a useful surface marker for
Th1-polarised T cells [21], we did not detect expression of this
marker on CI-activated, proliferating T cells (data not shown).
Generation of CI-responsive T-cell lines
We generated three CI-activated T-cell lines from three differ-
ent patients, all exhibiting a T-cell proliferative response to CI
(as determined by CFSE staining and flow cytometry). After in
vitro  activation of PBMCs with CI, the CFSElow population
(antigen-activated) was sorted by flow cytometry and
expanded with autologous, irradiated PBMCs, antigen, and IL-
2. All cell lines were CD3+CD4+CD8-CD28-
CD25+CD49a+(Figure 2).
Table 2
Collagen-specific T-cell response
CI response
Controls (n) 1/28 (3.6%)
Healthy (19)
Rheumatoid arthritis (9)
SSc 8/25 (32%)
Limited 5/17 (29.4%)
Diffuse 3/8 (37.5%)
Positive proliferative response to type I collagen (CI) was defined as 
a greater-than-twofold increase in proliferating cells (CFSElow) in the 
presence of CI. Approximately one third of patients with scleroderma 
(SSc) demonstrate reactivity to CI, which was significantly higher 
than the proportion of controls (healthy and rheumatoid arthritis 
combined) responsive to CI (p = 0.009).
Figure 2
Phenotypic analysis of type I collagen (CI)-responsive T-cell lines Phenotypic analysis of type I collagen (CI)-responsive T-cell lines. T cells were expanded in vitro with autologous peripheral blood mononuclear 
cells, interleukin-2, and antigen (CI). The resultant T-cell lines that proliferated to CI were CD3+CD4+CD8-CD28-CD25+CD49a+. Grey shaded 
areas represent staining with the appropriate isotype control.Arthritis Research & Therapy    Vol 8 No 4    Warrington et al.
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Cell line cytokine profile
We were interested in comparing the Th1 and Th2 cytokine
secretion profile of CI-specific cell lines. Cell lines generated
from three patients were activated in vitro for 72 hours with
plate-bound anti-CD3 (10 µg/ml) and anti-CD28 (1 µg/ml).
Cell culture supernatants were harvested and assayed for
cytokine content using a Bio-Plex assay. We detected abun-
dant Th1 cytokines, including IL-2, IFN-γ, and TNF-α. Th2
cytokines, including IL-4, IL-6, and IL-10, were present in much
lower amounts (Figure 3b). The chemotactic cytokine IL-8 was
also detected in the supernatant of CI-specific cells and is
likely responsible for the chemotactic properties of CI-acti-
vated PBMCs in the original publication of Stuart et al. [12].
To confirm our findings, we also analysed intracellular cytokine
production by flow cytometry, using fluorochrome-conjugated
antibodies to IFN-γ and IL-4 as representative cytokines of a
Th1 and Th2 profile, respectively. Indeed, intracellular IFN-γ
staining, but not IL-4 staining, was detected in our T-cell lines,
confirming the Bio-Plex data (Figure 3a).
Discussion
In this report, we demonstrate that in a subset of patients with
SSc, CI may behave as an autoantigen and induce prolifera-
tion of a specific CD4 T-cell subset that has a Th1 functional
profile.
Our results are consistent with a previous study [12] in which
25% of patients with SSc demonstrated lymphocyte prolifera-
tion in response to CI, as measured by [3H]-thymidine incorpo-
ration. However, previous studies implicating CI as an
autoantigen have not examined the phenotype or functional
profile of the antigen-specific cells. T cells that recognise a
particular antigen are present with very low frequency in the
blood, and therefore direct analysis is technically challenging.
We used CFSE labeling to allow identification of proliferating,
antigen-specific cells after in vitro stimulation with antigen
[22]. This technique was recently employed to study lym-
phocyte responses to peanut allergens in children with peanut
allergy [17]. The advantage of using CFSE over the traditional
[3H]-thymidine incorporation method is that antigen-specific
cells remain viable, allowing for phenotypic analysis, cell sep-
aration, and further expansion. Assessment of lymphocyte pro-
Figure 3
Th1 polarisation of type I collagen (CI)-responsive T-cell lines Th1 polarisation of type I collagen (CI)-responsive T-cell lines. Cytokine expression of T-cell lines was determined by intracellular (IC) staining of 
PMA (phorbol 12-myristate 13-acetate)/ionomycin activated T cells. (a) We detected interferon (IFN)-γ staining but no interleukin (IL)-4 staining. Mul-
tiplex cytokine assay was used to analyse the cytokine profile of three T-cell line supernatants. (b) An excess of Th1 over Th2 cytokines was 
detected. PE, phycoerythrin; TNF, tumour necrosis factor.Available online http://arthritis-research.com/content/8/4/R136
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liferation using CFSE/flow cytometry correlates well with
proliferation as measured by [3H]-thymidine incorporation, and
CFSE does not interfere with lymphocyte proliferation or func-
tion [17].
Mechanisms resulting in the breakdown of tolerance to CI are
as yet unknown. CI is the most abundant of all collagens in
humans. It is the most abundant collagen in skin, heart, and
intestines, all of which are affected in SSc. CI is a heterotrimer
molecule composed of two identical α-1(I) chains and one α-
2(I) chain, with each α chain containing 1,014 amino acid res-
idues. In mammals, CI is highly conserved, and there is a 92%
homology at the amino acid level between human and bovine
CI [23]. It is possible that the immune response to CI plays a
role in SSc disease pathogenesis or may be a secondary phe-
nomenon due to epitope spreading later in the disease proc-
ess. Immunity to CI has been described in other fibrotic
conditions, such as idiopathic pulmonary fibrosis [24] and ble-
omycin-induced pulmonary fibrosis [25]. Cellular immunity to
CI may also be representative of a more generalised immune
reactivity to extracellular matrix proteins in SSc. Laminin and,
less often, type IV collagen can induce proliferation of SSc
lymphocytes [16]. Autoantibodies to fibrillin-1, the major com-
ponent of microfibrils in the extracellular matrix, are present in
approximately one third of Caucasian patients with SSc [26].
In addition, both humoral and cellular immunities to elastin
have been described in a subset of patients with SSc [27].
The increased T-cell proliferation in response to CI in SSc may
be reflective of an altered activation state of PBMCs in this
condition. It has been demonstrated that CI can act as a
potent co-stimulatory molecule and induces proliferation of in
vitro activated CD4+ and CD8+ normal human T-cell lines in
the absence of antigen-presenting cells (APCs) [28]. Because
our experiments did not involve concomitant ligation of the T-
cell receptor with anti-CD3 and our experiments were con-
ducted with whole PBMC populations containing appropriate
APCs, it is unlikely that our results are due to co-stimulatory
properties of CI. However, it is also plausible that animal serum
in 'complete medium' may have resulted in non-specific T-cell
activation that was augmented in the collagen-stimulated cul-
tures.
The CD4+ phenotype of CI-specific T cells is consistent with
murine studies showing that type II collagen-specific T cells in
the collagen-induced arthritis mouse model also express a
CD4+ phenotype and express high levels of Th1 cytokines
[29]. CD28neg expression may reflect autoreactive properties
of these cells, as has been demonstrated in other autoimmune
diseases [30,31]. However, we cannot exclude the possibility
that CD28 loss occurred due to in vitro T-cell culture and
repeated activation, which is known to result in downregula-
tion of CD28 expression [32]. The expression of CD49a (VLA
[very late antigen]-1) on our CI-specific T-cell lines is in agree-
ment with the work of Goldstein et al. demonstrating that
CD49a+ T cells are a subset of Th1-polarised memory T cells
that proliferate in response to recall antigens [33].
The cytokine profile in SSc is skewed to a predominantly Th2
pattern, and this has direct consequences on the progression
of fibrosis [34,35]. In vitro, IL-4 promotes excess extracellular
matrix production [36], and Th2 cytokines in vivo are associ-
ated with increased lung fibrosis in SSc [37]. IL-10 also corre-
lates with increased disease severity, increased skin
thickness, and the presence of pulmonary fibrosis [38]. Inter-
estingly, CI-responsive T cells derived from patients with SSc
exhibited a Th1 profile, with a predominance of IL-2, IFN-γ, and
TNF-α. When human T cells are repeatedly stimulated in vitro,
they will often develop a Th2 phenotype [39], and therefore it
is unlikely that our results are due to the in vitro T-cell culture.
However, we cannot exclude the possibility that the IL-2
present in our cultures may have skewed T cells to a Th1 phe-
notype [40].
Expansion of Th1 T cells in vivo may be beneficial to limiting
disease progression. Lower serum IFN-γ levels have been
associated with active SSc [41]. Also, increased production of
IFN-γ by CI-activated PBMCs correlated with higher forced
vital capacity (Postlethwaite AE, personal communication),
consistent with the known anti-fibrotic properties of IFN-γ [42].
Patients whose bronchoalveolar lavage cells made IFN-γ
mRNA but not type 2 cytokines were noted to have preserved
forced vital capacity over time [37]. The production of TNF-α
by CI-specific T cells may also play a role in modulating the
homeostasis of extracellular matrix in SSc. Indeed, TNF-α pre-
vents the transforming growth factor-β-induced upregulation
of α-2(I) collagen and tissue inhibitor of metalloproteinases 1
in dermal fibroblasts [43] and directly stimulates the produc-
tion of matrix metalloproteinase-1 [44]. Our study was limited
to a fairly small sample size, making it difficult to perform
detailed correlations among disease phenotype, disease pro-
gression, and immune responses to CI.
However, the importance of immunity to CI is emphasised by
the finding that oral administration of CI to patients with SSc
modulates T-cell responses and may ameliorate the disease
[15]. Similar findings have been confirmed in a large multi-cen-
tre, placebo-controlled, randomised clinical trial that was
recently completed [45].
Conclusion
Circulating, memory CD4 T cells that proliferate in response to
CI are present in a subset of patients with SSc but are infre-
quent in healthy or disease controls. Determining T-cell
responses to CI in subsets of patients with SSc over time and
using methods employed in our study may help to identify
those who are most likely to benefit from CI-based immuno-
therapy.Arthritis Research & Therapy    Vol 8 No 4    Warrington et al.
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